Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.46 |
| ▸ | CA2 | P00918 | 8/20 | 0.46 |
| ▸ | CA9 | Q16790 | 7/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.46 |
| ▸ | CA7 | P43166 | 4/20 | 0.46 |
| ▸ | CA3 | P07451 | 3/20 | 0.46 |
| ▸ | CA4 | P22748 | 3/20 | 0.46 |
| ▸ | CA6 | P23280 | 3/20 | 0.46 |
| ▸ | CA5A | P35218 | 3/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9420457 | 0.83 | CA1 (0.48) | CA1CA2CA9CA12CA14 | |
| SCHEMBL19126866 | 0.82 | CA2 (0.59) | CA1CA2CA9CA12CA14 | |
| SCHEMBL18342911 | 0.81 | F2 (0.49) | CA1CA2CA9CA12CA14 | |
| SCHEMBL6754818 | 0.80 | HSD11B1 (0.47) | CA1CA2CA9CA12CA14 | |
| SCHEMBL82994 | 0.79 | CA1 (0.44) | CA1CA2CA9CA12CA14 | |
| SCHEMBL8605094 | 0.77 | ALDH1A1 (0.41) | CA2MMP1MMP8MMP13ALDH1A1 | |
| SCHEMBL619005 | 0.77 | LMNA (0.42) | CA2MMP1MMP8MMP13ALDH1A1 | |
| SCHEMBL6750246 | 0.77 | ALDH1A1 (0.47) | CA1CA2CA9CA12CA14 | |
| SCHEMBL64437 | 0.77 | ALDH1A1 (0.60) | ALDH1A1MAPT | |
| SCHEMBL28052 | 0.77 | PSIP1 (0.48) | HSD11B1MMP1MMP8MMP13ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209009-A1 | PEPTIDES COMPRISING A PHOSPHORYLCHOLINE CONJUGATE AND METHODS OF SYNTHESIZING SAME | TARSIER PHARMA LTD. (IL) | 2024-06-27 | — | — | US | claimed |
| US-20240199681-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | EVONETIX LTD (GB) | 2024-06-20 | — | — | US | claimed |
| WO-2024110477-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | WO | claimed |
| EP-4326738-A1 | PEPTIDES COMPRISING A PHOSPHORYLCHOLINE CONJUGATE AND METHODS OF SYNTHESIZING SAME | Tarsier Pharma Ltd. (IL) | 2024-02-28 | — | — | EP | claimed |
| EP-3720854-B1 | SOLID PHASE SYNTHESIS OF NIR FLUORESCENT PROBE | BRACCO IMAGING SPA (IT) | 2021-04-21 | — | — | EP | claimed |
| US-10954267-B2 | Dipeptide comprising a non-proteogenic amino acid | NOVO NORDISK A/S (DK) | 2021-03-23 | — | — | US | claimed |
| US-20210047361-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | SILICON VALLEY BANK | 2021-02-18 | — | — | US | claimed |
| EP-3743433-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | Evonetix Ltd (GB) | 2020-12-02 | — | — | EP | claimed |
| US-10822371-B2 | Solid phase synthesis of NIR fluorescent probe | BRACCO IMAGING S.P.A. (IT) | 2020-11-03 | — | — | US | claimed |
| EP-3720854-A1 | SOLID PHASE SYNTHESIS OF NIR FLUORESCENT PROBE | Bracco Imaging SpA (IT) | 2020-10-14 | — | — | EP | claimed |
| US-7282581-B2 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2007-10-16 | — | — | US | claimed |
| WO-2005095332-A1 | AMINO ACID DERIVATIVES USED AS AGENTS BONDING TO A SOLID SUPPORT | NEOMPS (FR) | 2005-10-13 | — | — | WO | claimed |
| US-6949639-B1 | Oligonucleotide labeling reactants and their use | WALLAC OY (FI) | 2005-09-27 | — | — | US | claimed |
| US-20040260080-A1 | Oligonucleotide labeling reactants and their use | HOVINEN JARI (FI) | 2004-12-23 | — | — | US | claimed |
| EP-0967205-B1 | Labeling reactants and their use | WALLAC OY (FI) | 2003-09-17 | — | — | EP | claimed |
| US-20030118999-A1 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2003-06-26 | — | — | US | claimed |
| EP-1308452-A2 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2003-05-07 | — | — | EP | claimed |
| EP-1152010-A2 | Oligonucleotide labeling reactants and their use | WALLAC OY (FI) | 2001-11-07 | — | — | EP | claimed |
| EP-0967205-A1 | Labeling reactants and their use | WALLAC OY (FI) | 1999-12-29 | — | — | EP | claimed |
| EP-0765307-B1 | N ALPHA-2-(4-NITROPHENYLSULFONYL)ETHOXYCARBONYL-AMINO ACIDS | HYUNDAI PHARM IND CO LTD (KR) | 1999-10-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199681-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | POLN, POLI, ADAR | CA1 2928/4885CA2 2353/4885CA9 2993/4885 |
| US-10954267-B2 | Dipeptide comprising a non-proteogenic amino acid | DNPEP, ANPEP, NPEPPS | CA1 1170/4885CA2 3238/4885CA9 3203/4885 |
| US-20240209009-A1 | PEPTIDES COMPRISING A PHOSPHORYLCHOLINE CONJUGATE AND METHODS OF SYNTHESIZING SAME | PTMS, SRMS, SGMS1 | CA1 976/4885CA2 2580/4885CA9 2413/4885 |
| US-20040260080-A1 | Oligonucleotide labeling reactants and their use | SSU72, LIG4, NSUN2 | CA1 1974/4885CA2 2093/4885CA9 1706/4885 |
| US-20030118999-A1 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | PCNA, DUT, POLL | CA1 1496/4885CA2 1502/4885CA9 1890/4885 |
| US-10822371-B2 | Solid phase synthesis of NIR fluorescent probe | MKI67, SSTR5, AURKA | CA1 471/4885CA2 2333/4885CA9 340/4885 |
| US-20210047361-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | POLN, POLI, ADAR | CA1 2928/4885CA2 2353/4885CA9 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.